Tags

Type your tag names separated by a space and hit enter

Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis.
Dig Dis Sci. 1990 May; 35(5):649-55.DD

Abstract

In a double-blind, randomized, comparative trial of the prokinetic drug cisapride and the H2-blocker cimetidine, mucosal healing and changes in symptoms of gastroesophageal reflux were evaluated in patients with erosive reflux esophagitis. The patients were treated with either cisapride, 10 mg four times a day (N = 36) or cimetidine, 400 mg four times a day (N = 37) for six weeks, or for 12 weeks if mucosal healing was not obtained by week 6. Upon entry, two thirds of the patients in each group had grade I (Savary-Miller) esophagitis, and the remainder grade II or III. At the end of treatment, endoscopy showed mucosal healing in 56% (38-72%; 95% confidence interval) of cisapride and 57% (39-73%; 95% confidence interval) of cimetidine patients. After six weeks, both drugs significantly (P less than 0.01) decreased the intensity and frequency of heartburn, regurgitation, and the postural syndrome. No significant intergroup differences were found regarding endoscopic parameters or the improvement of heartburn and regurgitation. Concomitant antacid use was also comparable. Adverse effects were reported by four cisapride and nine cimetidine patients. These results indicate that the effects of cisapride compare well with those of cimetidine in terms of both esophageal mucosal healing and symptom relief.

Authors+Show Affiliations

Centre Hospitalier Universitaire Nord, Nantes, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2331957

Citation

Galmiche, J P., et al. "Double-blind Comparison of Cisapride and Cimetidine in Treatment of Reflux Esophagitis." Digestive Diseases and Sciences, vol. 35, no. 5, 1990, pp. 649-55.
Galmiche JP, Fraitag B, Filoche B, et al. Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci. 1990;35(5):649-55.
Galmiche, J. P., Fraitag, B., Filoche, B., Evreux, M., Vitaux, J., Zeitoun, P., Fournet, J., & Soule, J. C. (1990). Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Digestive Diseases and Sciences, 35(5), 649-55.
Galmiche JP, et al. Double-blind Comparison of Cisapride and Cimetidine in Treatment of Reflux Esophagitis. Dig Dis Sci. 1990;35(5):649-55. PubMed PMID: 2331957.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Double-blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. AU - Galmiche,J P, AU - Fraitag,B, AU - Filoche,B, AU - Evreux,M, AU - Vitaux,J, AU - Zeitoun,P, AU - Fournet,J, AU - Soule,J C, PY - 1990/5/1/pubmed PY - 1990/5/1/medline PY - 1990/5/1/entrez SP - 649 EP - 55 JF - Digestive diseases and sciences JO - Dig. Dis. Sci. VL - 35 IS - 5 N2 - In a double-blind, randomized, comparative trial of the prokinetic drug cisapride and the H2-blocker cimetidine, mucosal healing and changes in symptoms of gastroesophageal reflux were evaluated in patients with erosive reflux esophagitis. The patients were treated with either cisapride, 10 mg four times a day (N = 36) or cimetidine, 400 mg four times a day (N = 37) for six weeks, or for 12 weeks if mucosal healing was not obtained by week 6. Upon entry, two thirds of the patients in each group had grade I (Savary-Miller) esophagitis, and the remainder grade II or III. At the end of treatment, endoscopy showed mucosal healing in 56% (38-72%; 95% confidence interval) of cisapride and 57% (39-73%; 95% confidence interval) of cimetidine patients. After six weeks, both drugs significantly (P less than 0.01) decreased the intensity and frequency of heartburn, regurgitation, and the postural syndrome. No significant intergroup differences were found regarding endoscopic parameters or the improvement of heartburn and regurgitation. Concomitant antacid use was also comparable. Adverse effects were reported by four cisapride and nine cimetidine patients. These results indicate that the effects of cisapride compare well with those of cimetidine in terms of both esophageal mucosal healing and symptom relief. SN - 0163-2116 UR - https://www.unboundmedicine.com/medline/citation/2331957/Double_blind_comparison_of_cisapride_and_cimetidine_in_treatment_of_reflux_esophagitis_ L2 - https://medlineplus.gov/gerd.html DB - PRIME DP - Unbound Medicine ER -